Press Releases Biotest AG Xetra

Equities

BIO

DE0005227201

Market Closed - Xetra Other stock markets 09:06:11 10/05/2024 pm IST			5-day change	1st Jan Change
41.6 ^EUR	-0.48%		-0.48%	-2.35%

07/05	Biotest Aktiengesellschaft Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
19/04	Biotest Launches New Plasma Collection Center in Germany	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Biotest : Speech of Peter Janssen - German Version	08/05	PU
Biotest AG: Annual General Meeting approves dividend distribution	07/05	EQ
Biotest increased sales by 83.6% to Euro 215.2 million in first quarter 2024	07/05	EQ
Biotest AG opens 12th plasma collection centre in Germany	19/04	EQ
Biotest AG increased sales by 32% in the financial year 2023	28/03	EQ
Biotest : Sustainability report Declaration of compliance 2023	28/03	PU
Biotest : Invitation / Agenda of Annual General Meeting 2024	26/03	PU
Biotest : Notes on agenda item 1 - German Version	25/03	PU
Biotest achieves EBIT forecast for 2023	29/02	EQ
Karl Lauterbach visits Biotest AG's plasma donation centre in Cologne and emphasises important contribution to patient care	28/02	EQ
Biotest successfully meets primary endpoint in phase III trial with Fibrinogen concentrate	14/02	EQ
AFR: Biotest AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]	30/01	EQ
AFR: Biotest AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]	22/01	EQ
Biotest AG opens 11th plasma collection centre in Germany	18/01	EQ
AFR: Biotest AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]	11/01	EQ
Biotest expands its clinical development program for trimodulin to patients with community-acquired pneumonia (CAP)	12/12	EQ
Biotest’s Trimodulin shows reduced mortality in patients with severe community-acquired pneumonia through rapid normalisation of inflammation	28/11	EQ
Biotest increases EBIT to Euro 125.4 million in the first nine months of 2023	02/11	EQ
Biotest AG: Increase of the EBIT guidance	05/23/05	EQ
Biotest AG: Peter Janssen appointed new Chairman of the Board of Biotest AG	05/23/05	EQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Biotest AG Xetra

Equities

BIO

DE0005227201

Press Releases

Filters